Patents by Inventor William Kreutner

William Kreutner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7960433
    Abstract: Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: June 14, 2011
    Assignee: Schering Corporation
    Inventors: Arthur G. Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay S. Fine, Loretta A. Bober, Jianhua Chao, Purakkattle J. Biju, Younong Yu
  • Publication number: 20070155756
    Abstract: Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).
    Type: Application
    Filed: February 14, 2007
    Publication date: July 5, 2007
    Inventors: Arthur Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay Fine, Loretta Bober, Jianhua Chao, Purakkattle Biju, Younong Yu
  • Publication number: 20070060608
    Abstract: A composition, method and kit comprising a compound for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin and other therapeutic compounds for the control or prevention of diseases states in which ?4?1 is involved.
    Type: Application
    Filed: November 7, 2003
    Publication date: March 15, 2007
    Applicants: ENCYSIVE PHARMACEUTICALS INC., SCHERING CORPORATION
    Inventors: Peter Vanderslice, George Holland, Neng Shih, Robert Asianian, Richard Chapman, William Kreutner
  • Publication number: 20040198743
    Abstract: The present invention includes methods of treating allergic skin conditions and disorders by combined administration of an histamine H1 receptor antagonist and a histamine H3 receptor antagonist.
    Type: Application
    Filed: January 29, 2004
    Publication date: October 7, 2004
    Applicant: Schering Corporation
    Inventors: John A. Hey, William Kreutner, Robbie L. McLeod
  • Publication number: 20040053953
    Abstract: Methods of treating chemokine-mediated diseases are disclosed.
    Type: Application
    Filed: March 17, 2003
    Publication date: March 18, 2004
    Applicant: Schering Corporation
    Inventors: Arthur G. Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay S. Fine, Loretta A. Bober, Jianhua Chao, Purakkattle J. Biju, Younong Yu
  • Patent number: 6599914
    Abstract: Methods of inhibiting the generation of pro-inflammatory cytokines such as IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: July 29, 2003
    Assignee: Schering Corporation
    Inventors: Robert P. Schleimer, John Schroeder, William Kreutner
  • Publication number: 20020183344
    Abstract: Methods of inhibiting the generation of pro-inflammatory cytokines such as IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.
    Type: Application
    Filed: April 24, 2001
    Publication date: December 5, 2002
    Inventors: Robert P. Schleimer, John Schroeder, William Kreutner
  • Patent number: 6472401
    Abstract: The present invention provides methods of treatment of mental and vascular disorders. In one embodiment, the present invention contemplates the administration of an anti-allergic medication to reduce a patient's symptoms of mental or vascular disorder. The patient may or may not suffer from allergic responses. Likewise, the methods of the present invention may be used to reduce or prevent the symptoms of a mental or vascular disorder. In a preferred embodiment, the anti-allergic medication is a non-sedating or low-sedating antihistamine such as loratadine or desloratadine.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: October 29, 2002
    Assignee: Schering Corporation
    Inventor: William Kreutner
  • Publication number: 20010006971
    Abstract: The present invention provides methods of treatment of mental and vascular disorders. In one embodiment, the present invention contemplates the administration of an anti-allergic medication to reduce a patient's symptoms of mental or vascular disorder. The patient may or may not suffer from allergic responses. Likewise, the methods of the present invention may be used to reduce or prevent the symptoms of a mental or vascular disorder. In a preferred embodiment, the anti-allergic medication is a non-sedating or low-sedating antihistamine.
    Type: Application
    Filed: January 12, 2001
    Publication date: July 5, 2001
    Inventor: William Kreutner
  • Patent number: 6140337
    Abstract: The present invention provides methods of treatment of mental disorders comprising administering the anti-allergic medication loratadine or a metabolite thereof to reduce a patient's symptoms of a mental disorder.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: October 31, 2000
    Assignee: Schering Corporation
    Inventors: Gary Binder, Domenic G. Iezzoni, William Kreutner, Arnold Lash
  • Patent number: 5929236
    Abstract: Disclosed are compounds of the formula I wherein:Y represents --CO.sub.2 H, --CO.sub.2 R.sup.6, --C(O)NHR.sup.7, --SO.sub.2 H, --SO.sub.3 H, --SO.sub.3 R.sup.6, --SO.sub.2 NHR.sup.7, --C(O)--N(OH)--R.sup.8, or a group of the formula ##STR1## or a pharmaceutically acceptable addition salt or solvate thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I. Further disclosed is a method for treating or preventing respiratory depression, epileptic seizures or other central nervous system disorders, and for enhancing cognitive performance, by administering an effective amount of a compound of Formula I.
    Type: Grant
    Filed: September 22, 1995
    Date of Patent: July 27, 1999
    Assignee: Schering Corporation
    Inventors: Shen-Chun Kuo, David J. Blythin, William Kreutner
  • Patent number: 5869479
    Abstract: Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H.sub.1 receptor antagonist; together with (b) a sufficient amount of a histamine H.sub.3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or separately in the same or different dosage forms to maintain therapeutic systemic levels of both components.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: February 9, 1999
    Assignee: Schering Corporation
    Inventors: William Kreutner, John A. Hey
  • Patent number: 5006560
    Abstract: A method for treating cough in a mammal comprising administering to said mammal an anti-tussive effective amount of a GABA-B selective agonist such as ##STR1## is described.
    Type: Grant
    Filed: December 20, 1989
    Date of Patent: April 9, 1991
    Assignee: Schering Corporation
    Inventors: William Kreutner, Donald Bolser, Richard Chapman, Sultan Aziz
  • Patent number: 4782082
    Abstract: Forskolin and its disclosed derivatives are useful as antiallergic agents. Certain of the derivatives are novel.
    Type: Grant
    Filed: August 7, 1986
    Date of Patent: November 1, 1988
    Assignee: Schering Corporation
    Inventors: William Kreutner, Michael J. Green, Ho-Jane Shue, Anil K. Saksena
  • Patent number: 4564626
    Abstract: A method for producing bronchodilation in a mammal is disclosed. Composition for use in said method are also described.
    Type: Grant
    Filed: April 1, 1983
    Date of Patent: January 14, 1986
    Assignee: Schering Corporation
    Inventors: William Kreutner, Marvin I. Siegel
  • Patent number: 4517200
    Abstract: Forskolin and its disclosed derivatives are useful as antiallergic agents. Certain of the derivatives are novel.
    Type: Grant
    Filed: October 17, 1983
    Date of Patent: May 14, 1985
    Assignee: Schering-Plough Corporation
    Inventors: William Kreutner, Michael J. Green, Ho-Jane Shue, Anil K. Saksena